Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Relay Therapeutics (RLAY) over the last 3 years, with Jun 2025 value amounting to -10,424.82%.

  • Relay Therapeutics' EBITDA Margin was N/A to -10,424.82% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,690.30%, marking a year-over-year change of. This contributed to the annual value of -3,382.66% for FY2024, which is 208403.00% down from last year.
  • As of Q2 2025, Relay Therapeutics' EBITDA Margin stood at -10,424.82%, which was down 952.82% from -990.18% recorded in Q1 2025.
  • Over the past 5 years, Relay Therapeutics' EBITDA Margin peaked at 8,030,500.00% during Q4 2023, and registered a low of -83,011.76% during Q2 2023.
  • For the 3-year period, Relay Therapeutics' EBITDA Margin averaged around 1,127,906.41%, with its median value being -990.18% (2025).
  • As far as peak fluctuations go, Relay Therapeutics' EBITDA Margin slumped by 73,978,297bps in 2021, and later soared by 805,600,751bps in 2023.
  • Over the past 5 years, Relay Therapeutics' EBITDA Margin (Quarterly) stood at -12,090.65% in 2021, then crashed by 1,341,686bps to -25,507.51% in 2022, then soared by 805,600,751bps to 8,030,500.00% in 2023, then soared by 3,883,240bps to -822.91% in 2024, then plummeted by 16,727bps to -10,424.82% in 2025.
  • Its last three reported values are -10,424.82% in Q2 2025, -990.18% for Q1 2025, and -822.91% during Q1 2024.